Back to results
US 2023/0390367 A1Published application
Genetic approach to suppress coronaviruses
AssigneeTemple University of the Commonwealth System of Higher Education
InventorsKamel Khalili, Rafal Kaminski, Shuren Liao
Life of this patent
Estimating the term…
Abstract
Compositions include gene editing agents, e.g. CRISPR that employ Cas13a for editing and inactivating sequences in the Coronavirus genome.
Claims30
A method of treating a coronavirus infection, comprising:
- administering to a subject in need of such treatment a composition comprising a therapeutically effective amount of one or more gene-editing agents, wherein the gene editing agents are targeted to one or more coronavirus gene sequences,
- thereby treating the subject.
A composition comprising:
- a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease or a nucleic acid sequence encoding the CRISPR-associated endonuclease;
- a first guide RNA (gRNA) or a nucleic acid sequence encoding the first gRNA, the first gRNA being complementary to a first target nucleic acid sequence within a coronavirus target sequence;
- and
- a second guide RNA or a nucleic acid sequence encoding the second gRNA, the second gRNA being complementary to a second target nucleic acid sequence within the coronavirus target sequence, the second gRNA being different from the first gRNA;
- wherein the coronavirus genome between the two gRNAs are excised.
2 more elements
A composition comprising:
- a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease or a nucleic acid sequence encoding the CRISPR-associated endonuclease;
- and,
- at least one guide RNA (gRNA) or a nucleic acid sequence encoding the gRNA, the gRNA being complementary to a target nucleic acid sequence within a coronavirus target sequence.
Dependencies are inferred from the claim text.